Ignite Creation Date:
2024-05-05 @ 12:03 PM
Last Modification Date:
2024-10-26 @ 9:19 AM
Study NCT ID:
NCT00231426
Status:
COMPLETED
Last Update Posted:
2006-11-22
First Post:
2005-09-30
Brief Title:
ASSURE Study - Arrhythmia Single Shock DFT Versus ULV Risk Reduction Evaluation With ICD Implantations
Sponsor:
Boston Scientific Corporation
Organization:
Boston Scientific Corporation
Study Overview
Official Title:
Arrhythmia Single Shock DFT Versus ULV Risk Reduction Evaluation With ICDs Study
Status:
COMPLETED
Status Verified Date:
2006-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The ASSURE Study will evaluate shock conversion performance when programming the first shock of an implantable cardioverter-defibrillation ICD is based on an implant test consisting of either 1 a single induction of ventricular fibrillation VF and subsequent demonstration conversion success at 14 J or 2 an upper limit of vulnerability ULV test at 14 J
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None